Today: 23 November 2025
Subscribe
Browse Category

Investment Strategies News 17 October 2025 - 19 October 2025

Datavault AI (DVLT) Stock Skyrockets on Bitcoin Deal & AI Hype – Is the 400% Rally Sustainable?

Datavault AI (DVLT) Stock Skyrockets on Bitcoin Deal & AI Hype – Is the 400% Rally Sustainable?

What to Know Before Markets Open on October 20, 2025 Market Reaction: Wild Swings and Heavy Trading Datavault AI’s stock has been on a wild roller-coaster in recent days as investors react to the company’s bold moves. After steadily climbing above $1 through early October – a threshold that allowed DVLT to regain Nasdaq compliance on Oct. 10, removing prior delisting risk ts2.tech – the stock went into overdrive. News of the massive Bitcoin-funded investment and optimistic guidance ignited a retail trading frenzy. Shares that traded at about $0.50 a month ago suddenly spiked to an intraday peak near $2.70–$3.00
19 October 2025
 ·  ·  ·  ·  ·  ·  · 
Applied Materials (AMAT) Stock Near Record Highs on AI Chip Boom – Can the Rally Survive China Curbs?

Applied Materials (AMAT) Stock Near Record Highs on AI Chip Boom – Can the Rally Survive China Curbs?

What to Know Before Markets Open on October 20, 2025 Stock Price and Recent Performance 📈 Applied Materials’ stock has been on a tear in October, climbing to levels not seen in over a year. As of October 19, 2025 (last market close Oct. 17), AMAT traded around $225/share, just shy of its 52-week high (~$232 intraday) investing.com investing.com. The stock is up approximately 15% year-to-date and a remarkable 50%+ in the past six months, far outpacing the broader market investing.com. Recent action has been especially volatile: shares jumped over 4% on Wednesday alone, then essentially flatlined Thursday near record
19 October 2025
 ·  ·  ·  ·  · 
Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Stock Performance & Analyst Consensus Intuitive’s stock has been volatile in 2025. It gained ground last week on optimism (e.g. up ~2.7% on Oct. 17) and now sits around $446 investing.com marketbeat.com. Over the past year, the price swung between about $425 and $616 investing.com. At ~$446, ISRG trades at a high single-digit P/E (~60x) compared to the medtech sector, but analysts argue much of Intuitive’s growth is already priced in. Institutional sentiment is upbeat: 22 of 32 surveyed analysts rate ISRG a Buy, with an average 12-month target of roughly $576 investing.com (implying ~29% upside). For example, RBC Capital
19 October 2025
 ·  ·  ·  ·  · 
Starbucks (SBUX) Brewing Gains? CEO’s Shake-Up & $5B China Deal Fuel Stock Rally

Starbucks (SBUX) Brewing Gains? CEO’s Shake-Up & $5B China Deal Fuel Stock Rally

Starbucks stock trades in the mid-$80s (Nasdaq: SBUX) after a recent bounce; it remains down about 9–10% over the past year ts2.tech simplywall.st. CEO Brian Niccol has launched a $1 billion Back to Starbucks” turnaround – closing roughly 1% of U.S./Canada stores (several hundred locations) and cutting ~900 corporate jobs ts2.tech reuters.com. Q3 FY2025 results (ended July) were weak: EPS $0.50 (missing consensus) and profit plunged ~47% YOY on higher costs ts2.tech marketbeat.com. Wall Street is cautiously optimistic: ~⅔ of analysts rate SBUX a Buy, with an average 12‑month target around $100–105 (roughly 17–20% above current prices) ts2.tech stockanalysis.com. Labor tensions
18 October 2025
 ·  ·  ·  ·  · 
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

In summary, Gilead’s share price has rallied on a wave of HIV-related breakthroughs, pipeline achievements, and upbeat guidance. With third-quarter results due Oct. 30, investors will be watching for sustained growth. For now, analysts remain generally optimistic: the consensus rating is Buy” (with average target ~$125) based on Gilead’s diversified portfolio and innovation investing.com ts2.tech. As management shifts into high gear on oncology and global health programs (e.g. a PEPFAR-backed plan to deliver Yeztugo overseas), the long-term outlook is that Gilead’s multiple drivers will more than offset sector risks. Sources: Recent financial filings and earnings commentary gilead.com stockanalysis.com; industry news
18 October 2025
 ·  ·  ·  · 
Liberty Energy’s Rollercoaster: LBRT Surges on Earnings Despite Oilfield Headwinds

Liberty Energy (LBRT) Stock Soars 28% on Earnings Surprise – Can the Rally Last?

Key Facts – October 18, 2025 Stock Skyrockets on Earnings News Liberty Energy’s latest earnings release sparked a stunning rally in its stock. On October 17, the day after results, LBRT jumped over 20% intraday, hitting the mid-$15 range ts2.tech. It ultimately closed at $15.32 on Friday (Oct 17), up 28.3% in one day reuters.com – an eye-catching move on a day when broader markets were relatively quiet. The stock had closed at $11.94 the previous day reuters.com, so investors added roughly $3.4 per share of value overnight in response to the news. This burst of buying follows a prolonged
18 October 2025
 ·  ·  ·  ·  · 
Alibaba Stock Soars on AI Frenzy – Can the Rally Last?

Alibaba’s 2025 Comeback: AI Ambitions Fuel BABA Stock Rally – Will It Last?

Stock Price and Market Performance (Oct. 17 Update) Alibaba’s stock is capping off a strong week, with a notable move on October 17, 2025. The NYSE-listed BABA shares closed around $167 on Friday, recovering from early-session weakness. This roughly 3% intraday rebound came despite a sell-off in Hong Kong, where Alibaba’s secondary listing fell over 4% amid broad tech declines. Even with recent volatility, Alibaba’s U.S. stock remains near multi-year highs – up about 85–90% year-to-date ts2.tech. By comparison, the NYSE Composite index is only up ~12% in 2025 ts2.tech, underscoring Alibaba’s outsized rally. The stock’s momentum since spring carried
17 October 2025
 ·  ·  ·  ·  · 
Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

FDA Setback Triggers Strategic Review Kezar Life Sciences revealed a major regulatory setback for its lead drug and immediately pivoted to consider strategic alternatives. In an October 16 press release, the South San Francisco company announced it failed to reach alignment with the U.S. Food and Drug Administration on the design of a pivotal trial for zetomipzomib in autoimmune hepatitis (AIH) ca.investing.com. The FDA abruptly canceled a Type C meeting that was scheduled for Q4 2025 to discuss Kezar’s proposed Phase 3 trial, and instead requested a new standalone study to characterize zetomipzomib’s pharmacokinetics in patients with severe liver impairment
17 October 2025
 ·  ·  ·  ·  · 
J.B. Hunt (JBHT) Stock Soars on Earnings Surprise – Is a Freight Sector Revival Underway?

J.B. Hunt Stock Skyrockets 22% After Earnings Shock – Can the Rally Hold?

J.B. Hunt’s corporate headquarters in Lowell, Arkansas. The trucking giant delivered an earnings surprise that sent its stock soaring. Stock Rockets on Earnings Beat J.B. Hunt’s stock exploded higher after the company’s third-quarter results blew past expectations. Shares surged from about $139 (Wednesday’s close) to $169.57 by Thursday’s close, a 22.1% one-day leap finviz.com. Investors haven’t seen a move like that in years – the best single-day gain in decades for J.B. Hunt’s stock, according to market watchers. The price spike came on unusually heavy trading volume (6.5 million shares traded vs. an average of ~1–2 million), reflecting intense interest
17 October 2025
 ·  ·  ·  ·  · 
SLB Stock Q3 Beat, $4B Buybacks & Oil Swoon: Will Schlumberger (SLB) Rebound?

SLB Stock Q3 Beat, $4B Buybacks & Oil Swoon: Will Schlumberger (SLB) Rebound?

Q3 Earnings Recap: Resilient Results Amid Oil Slowdown SLB’s third-quarter 2025 results, released on Oct 17, showed better-than-expected profitability even as industry conditions softened. The company earned $0.69 per share (adj.) for Q3, topping estimates of $0.66 tipranks.com. Revenue came in at $8.93 billion, essentially on target tipranks.com. Both metrics were down modestly from a year ago (EPS was $0.89, revenue $9.16 B in Q3 2024) as global drilling activity has cooled. CEO Olivier Le Peuch described the quarter as resilient,” noting SLB expanded its EBITDA margins and generated $1.8 B in free cash flow, thanks to efficiency gains investing.com investing.com. North America
17 October 2025
 ·  ·  ·  ·  · 
Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

In summary, Artiva Biotherapeutics stock has erupted in October 2025 on the back of a major FDA Fast Track win and renewed optimism around its NK-cell therapy for RA. The latest developments – from surging share price and volume to analyst projections of multi-fold upside – underscore the high stakes and high hopes riding on AlloNK’s success. For biotech investors and observers, ARTV will be a stock to watch closely in the coming months, as upcoming trial data and FDA feedback chart the next chapter for this promising yet still speculative biotech play. Latest Stock Price and Trend Analysis 247marketnews.com
17 October 2025
 ·  ·  ·  ·  · 
Reliance Q2 Results Boost Investor Hopes – Double-Digit Growth, Jio IPO Buzz & Stock Breakout?

Reliance Q2 Results Boost Investor Hopes – Double-Digit Growth, Jio IPO Buzz & Stock Breakout?

RIL Q2 Earnings Signal Steady Growth Across Businesses Mumbai, Oct 17, 2025 (News Report): Reliance Industries – India’s largest company by market value – announced its July–September quarter results on Friday, delivering a solid performance amid high investor expectations. Early indications from brokerage estimates suggest double-digit growth in both profit and revenue for Q2 FY2026, driven by strength in RIL’s core businesses. Analysts had widely predicted a healthy double-digit rise in consolidated revenue and profit” year-on-year livemint.com, and RIL appears to have largely met those optimistic forecasts. This comes after an extraordinary Q1 where Reliance booked record profits thanks to
17 October 2025
 ·  ·  ·  · 
1 … 17 18 19 20 21 … 25
Go toTop